Similarly, a combination of the best dtEV formulation (1/1/1 TP53-mRNA/siKRASG12D/siGli1 and a higher dose of Gemcitabine (50 mg/kg) did not fully suppress the tumor growth in an aggressive orthotopic PDX PDAC mouse model (Fig. 8). The gene discussed is TP53; the disease is neoplasm.